|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||160.73 - 165.15|
|52-week range||133.65 - 179.92|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||24.63|
|Earnings date||19 Oct 2021|
|Forward dividend & yield||4.24 (2.59%)|
|Ex-dividend date||23 Aug 2021|
|1y target est||188.88|
Thierry Bernard, QIAGEN CEO, joins Yahoo Finance to discuss the future of Covid-19 testing, interest and supply of at-home covid testing, and the diagnostic industry amid the pandemic.
The "tl;dr" (too long, didn't read) scoop on Johnson & Johnson's (NYSE: JNJ) third-quarter results is that they were good overall. J&J's shares opened around 1% higher and picked up more momentum later in the day. Here are three things you might have missed in Johnson & Johnson's Q3 results.
The healthcare giant recorded healthy growth in all three of its business segments and raised its guidance.